HNB
DRNA

Huntington National Bank’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Huntington National Bank’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-500
Closed -$4K – 1725
2015
Q3 		$4K Buy
+500
New +$5.77K ﹤0.01% 1568

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Huntington National Bank's DRNA Position: Q4 2015 in Review

Huntington National Bank sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2015, closing a stake of 500 shares — an estimated $4K sold.

Huntington National Bank first reported a position in DRNA in Q3 2015 and held it in 1 quarter. The position peaked at $4K in Q3 2015. 58 funds tracked by Wall St. Rank hold DRNA as of Q4 2015.

  • Huntington National Bank reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Huntington National Bank sold 500 Dicerna Pharmaceuticals, Inc. shares in Q4 2015, an estimated $4K.
  • Huntington National Bank first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Huntington National Bank's Dicerna Pharmaceuticals, Inc. position peaked at $4K in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2015.

Based on Huntington National Bank's 13F filing for Q4 2015, filed 2 Feb 2016.